New drug aims to slow Alzheimer's by targeting tau tangles

NCT ID NCT06372821

Recruiting now Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Jan 28, 2026 · Last updated Apr 25, 2026 · Updated 14 times

Summary

This early-phase study tests whether a drug called NIO752 can reduce the brain's production of tau, a protein that forms harmful tangles in Alzheimer's disease. Ten adults with mild to moderate Alzheimer's will receive either the drug or a placebo via spinal injection. The main goal is to measure changes in tau levels in spinal fluid over 20 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University College London Hospitals NHS Foundation Trust
RECRUITING

London, NW1 2PG, United Kingdom

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Washington University in St. Louis
RECRUITING

St Louis, Missouri, 63110, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ALZHEIMER DISEASE AUTOSOMAL DOMINANT ALZHEIMER DISEASE DUE TO MUTATION OF AMYLOID PRECURSOR PROTEIN (DISORDER) AUTOSOMAL DOMINANT ALZHEIMER DISEASE DUE TO MUTATION OF PRESENILIN 1 (DISORDER) AUTOSOMAL DOMINANT ALZHEIMER DISEASE DUE TO MUTATION OF PRESENILIN 2 (DISORDER)